<DOC>
	<DOCNO>NCT02442817</DOCNO>
	<brief_summary>The purpose present study gather pilot data effect linagliptin concentration long short form SDF1-α ( stromal cell-derived factor alpha ) human , demonstrate feasibility study patient psychosis set .</brief_summary>
	<brief_title>Linagliptin Mesenchymal Stem Cells : A Pilot Study</brief_title>
	<detailed_description>This study 13-week , open-label study 8 participant schizophrenia minimal think disorder ; 12 week treatment week assessment . They receive linagliptin , 5 mg mouth per day , continue antipsychotic treatment . The principal outcome measure concentration long short form SDF1-α ( stromal cell-derived factor alpha ) blood .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Meets DSM ( Diagnostic Statistical Manual ) criterion schizophrenia . Considered clinically stable , dose antipsychotic two week . A score great 3 PANSS ( Positive Negative Syndrome Scale ) Conceptual Disorganization item . Not take medication diabetes , antiinflammatories occasional aspirin acetaminophen . Not take Clozapine . Age 1845 year . Can available regular morning appointment 8:00 10:00 , preferably Tuesdays , Wednesdays Thursdays . Does meet DSM criterion substance abuse dependence . No serious current general medical condition , cancer , history stroke myocardial infarction , tuberculosis , HIV/AIDS , hemophilia , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DPP-4 Inhibitor</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>SDF1-α</keyword>
</DOC>